Printer Friendly

ALPHA 1 BIOMEDICALS, INC. REPORTS THIRD QUARTER CALENDAR YEAR 1992 RESULTS

 ALPHA 1 BIOMEDICALS, INC. REPORTS
 THIRD QUARTER CALENDAR YEAR 1992 RESULTS
 BETHESDA, Md., Nov. 11 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) today reported financial results for the third quarter of calendar year 1992.
 Revenues for the third quarter were $41,964 and expenses were $1,284,364 resulting in a net loss of $1,242,400 or 17 cents per share. The results for the same quarter of the preceding year were $66,208 in revenues, $932,174 in expenses and a loss of $865,966 or 13 cents per share.
 For the first nine months, revenues of $159,104 and expenses of $3,303,780 resulted in a loss of $3,144,676 or 43 cents per share. The results for the comparable period a year earlier were revenues of $127,836 and expenses of $2,376,816 for a loss of $2,248,980 or 34 cents per share,.
 Reported losses for the quarter and nine month period were in line with management's expectations and are primarily associated with expenses of ongoing clinical trials and operating costs.
 The company's product inventory has increased this calendar year to accommodate orders received from its foreign licensees. In this regard, the company has received more than $350,000 in advance payments, which have been recorded as unearned revenue. The company anticipates revenue for these orders during the current calendar year when Thymosin alpha 1 is exported.
 Alpha 1 Biomedicals, Inc. is a Bethesda-based company engaged in the development of pharmaceutical products.
 ALPHA 1 BIOMEDICALS, INC.
 Statement of Operations
 (Unaudited)
 Periods ended Sept. 30, 1992 1991 1992 1991
 Revenue $41,964 $66,208 $159,104 $127,836
 Expenses 1,284,364 932,174 3,303,780 2,376,816
 Net loss 1,242,400 865,966 3,144,676 2,248,980
 Net loss per common share $0.17 $0.13 $0.43 $0.34
 Weighted average common
 shares outstanding 7,326,657 6,927,058 7,314,147 6,527,195
 -0- 11/11/92
 /CONTACT: R. J. Lanham, vice president-finance and administration of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals, Inc./
 (ALBM) CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: ERN


SH-TS -- NY010 -- 9635 11/11/92 09:52 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1992
Words:384
Previous Article:TENNECO NAMES THEODORE AUSTELL DIRECTOR, GOVERNMENT RELATIONS
Next Article:GRC INTERNATIONAL, INC. SUBSIDIARY WINS $1 MILLION NAVAL RESEARCH LABORATORY DEVELOPMENT AND INTEGRATION CONTRACT
Topics:


Related Articles
VIRATEK REPORTS SECOND QUARTER SALES AND EARNINGS
BIOGEN ANTICIPATES SIGNIFICANT INCREASE IN 1992 REVENUES AND EARNINGS
U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS
ALPHA 1 BIOMEDICALS ANNOUNCES REVISIONS TO TERMS OF THE REDEMPTION OF ITS CLASS B WARRANTS
ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION
ALPHA 1 BIOMEDICALS, INC. FOURTH QUARTER AND CALENDAR YEAR 1992 RESULTS
ENROLLMENT COMPLETED IN ALPHA 1 BIOMEDICALS' PHASE III CLINICAL TRIAL
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
ICN BIOMEDICALS REPORTS FIRST QUARTER EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters